John Shine
Corporate Officer/Principal chez The University of New South Wales
Profil
John Shine is currently a Professor of Molecular Biology & Medicine at The University of New South Wales.
Previously, he served as the Chairman of CSL Ltd.
from 2011 to 2018.
He also held positions as the Chairman of the National Health & Medical Research Council, Director of G2 Therapies Pty Ltd., Director of The Garvan Institute of Medical Research from 2011 to 2012, Director of Garvan Research Foundation, Member of the Prime Minister's Science, Engineering & Innovation Council, and President of the Museum of Applied Arts & Sciences.
Postes actifs de John Shine
| Sociétés | Poste | Début |
|---|---|---|
| The University of New South Wales | Corporate Officer/Principal | 29/10/2010 |
Anciens postes connus de John Shine
| Sociétés | Poste | Fin |
|---|---|---|
| CSL LIMITED | Président | 17/10/2018 |
The Garvan Institute of Medical Research
 The Garvan Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia. | Directeur/Membre du Conseil | 01/01/2012 |
| Museum of Applied Arts & Sciences | President | - |
| Prime Minister's Science, Engineering & Innovation Council | Corporate Officer/Principal | - |
| National Health & Medical Research Council | Président | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CSL LIMITED | Health Technology |
| Entreprise privées | 6 |
|---|---|
G2 Therapies Pty Ltd.
 G2 Therapies Pty Ltd. BiotechnologyHealth Technology G2 Therapies Pty Ltd. develops novel antibody based therapies in inflammation and cancer. G2 used novel techniques to raise potent neutralising antibodies to the entire cell surface target of several 7-transmembrane domain chemoattractant receptors (GPCRs). The company was founded by Charles Reay Macaky in 2002 and is headquartered in Darlinghurst, Australia. | Health Technology |
The Garvan Institute of Medical Research
The Garvan Institute of Medical Research Miscellaneous Commercial ServicesCommercial Services The Garvan Institute of Medical Research engages in the provision of biomedical research. It focuses in cancer, genomics and epigenetics, immunity and inflammation, healthy ageing, clinical trials, and research centres. The company was founded in 1963 and is headquartered in Darlinghurst, Australia. | Commercial Services |
| Garvan Research Foundation | |
| National Health & Medical Research Council | Government |
| Prime Minister's Science, Engineering & Innovation Council | |
| Museum of Applied Arts & Sciences |
